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In mucosal drug delivery, two design goals are desirable: 1) insure drug passage through the mu-
cosal barrier to the epithelium prior to drug removal from the respective organ via mucus clearance;
and 2) design carrier particles to achieve a prescribed arrival time and drug uptake schedule at the
epithelium. Both goals are achievable if one can control "one-sided" diffusive passage times of drug
carrier particles: from deposition at the mucus interface, through the mucosal barrier, to the epithe-
lium. The passage time distribution must be, with high confidence, shorter than the timescales of
mucus clearance to maximize drug uptake. For 100 nm and smaller drug-loaded nanoparticulates,
as well as pure drug powders or drug solutions, diffusion is normal (i.e., Brownian) and rapid, easily
passing through the mucosal barrier prior to clearance. Major challenges in quantitative control over
mucosal drug delivery lie with larger drug-loaded nanoparticulates that are comparable to or larger
than the pores within the mucus gel network, for which diffusion is not simple Brownian motion
and typically much less rapid; in these scenarios, a timescale competition ensues between particle
passage through the mucus barrier and mucus clearance from the organ. In the lung, as a primary
example, coordinated cilia and air drag continuously transport mucus toward the trachea, where
mucus and trapped cargo are swallowed into the digestive tract. Mucus clearance times in lung
airways range from minutes to hours or significantly longer depending on deposition in the upper,
middle, lower airways and on lung health, giving a wide time window for drug-loaded particle design
to achieve controlled delivery to the epithelium. We review the physical and chemical factors (of
both particles and mucus) that dictate particle diffusion in mucus, and the technological strategies
(theoretical and experimental) required to achieve the design goals. First we describe an idealized
scenario — a homogeneous viscous fluid of uniform depth with a particle undergoing passive normal
diffusion — where the theory of Brownian motion affords the ability to rigorously specify particle
size distributions to meet a prescribed, one-sided, diffusive passage time distribution. Furthermore,
we describe how the theory of Brownian motion provides the scaling of one-sided diffusive passage
times with respect to mucus viscosity and layer depth, and under reasonable caveats, one can also
prescribe passage time scaling due to heterogeneity in viscosity and layer depth. Small-molecule
drugs and muco-inert, drug-loaded carrier particles 100 nm and smaller fall into this class of rigor-
ously controllable passage times for drug delivery. Second we describe the prevalent scenarios in
which drug-loaded carrier particles in mucus violate simple Brownian motion, instead exhibiting
anomalous sub-diffusion, for which all theoretical control over diffusive passage times is lost, and
experiments are prohibitive if not impossible to measure one-sided passage times. We then discuss
strategies to overcome these roadblocks, requiring new particle-tracking experiments and emerging
advances in theory and computation of anomalous, sub-diffusive processes that are necessary to
predict and control one-sided particle passage times from deposition at the mucosal interface to
epithelial uptake. We highlight progress to date, remaining hurdles, and prospects for achieving the
two design goals for 200 nm and larger, drug-loaded, non-dissolving, nanoparticulates.
1. INTRODUCTION
Inhaled drug delivery must overcome the same primary
defense mechanism that Nature has engineered to pre-
vent all inhaled insults from engagement with and ab-
sorption by lung epithelial tissue: the mucosal barrier
∗ forest@unc.edu
[1]. Mucus likewise coats the nasal, sinus, digestive, and
reproductive tracts, and indeed all organs not covered by
skin. Mucus layers present a diffusive barrier to viruses
(∼100 nm), bacteria (microns), environmental particu-
lates and drug particles spanning nanometers to microns.
For inhaled small molecule drugs typically delivered with
nebulizer sprays, or with powder particles that dissolve
instantly upon landing at the air-mucus interface, drug

















FIG. 1. Diagram depicting the effect of particle size on the nature (Brownian vs. non-Brownian) of diffusive motion in mucus
barriers. Class 1: Small molecules and drug-loaded nanoparticulates 100 nm or smaller that do not chemically bind to the mucus
mesh are minimally affected by the mucus microstructure and rapidly move via Brownian motion through the barrier. Class 2:
Muco-inert particles of size proportional to mucus pores experience steric interactions with the mesh and entropic fluctuations
from the mucus gel microstructure. Their increments are not only reduced relative to freely diffusing smaller particles, they
are correlated, violating Brownian motion. Class 3: Muco-inert particles much larger than the mucus pores, e.g., 500 nm to
1 micron depending on the mucus source, experience the full range of entropic fluctuations from the mucus microstructure,
and are the ideal probes for particle-tracking microrheology. These particle increments are likewise correlated, reflecting elastic
memory of the mucus gel, and exhibit transient, anomalous, sub-diffusive behavior. Class 2 and 3 particles with adhesive
or repulsive interactions to the mucus mesh exhibit a wide range of mobilities that, with rare exception, also violate simple
Brownian motion. Advanced particle-tracking experiments of drug-loaded nanoparticulates, ranging from 200 nm to microns,
are required to give sufficient data to select among possible models for transient, anomalous, sub-diffusion, and to properly
estimate best-fit model parameters. From these results, due to the absence of theory for passage times of such non-Brownian
processes, model computations become the required technology to estimate one-sided passage times through mucus barriers.
ian motion and is instantaneous relative to mucus clear-
ance times. Drug molecules or particles that tightly bind
to the mucus microstructure, or that diffuse sufficiently
slowly, are removed by mucus clearance. (All organs not
covered by skin have mucus barriers for muco-trapping of
insults, with organ-specific mucus clearance mechanisms
to remove trapped insults before they penetrate the bar-
rier, and mucus replenishment sources to maintain the
barrier.)
For all other drug-loaded carrier particles that are suffi-
ciently large (200 nm and larger), not permanently bound
to the mucus mesh, and do not dissolve in mucus prior to
contact with epithelial tissue or clearance from the pro-
tected organ, their diffusion in mucus is not described
by simple Brownian motion. This has profound conse-
quences for being able to control passage times through
a mucus barrier. Particle diffusive passage times through
a mucus barrier of known depth varies dramatically (po-
tentially many orders of magnitude) depending on size
and chemical properties of the particle and biophysical
properties of the mucus. Furthermore, there is no theory
for passage times, nor how they scale with depth of a
layer or with heterogeneity of the fluid, for anomalous,
transient, sub-diffusion. Mucus itself varies dramatically
from human to human, organ to organ, health to dis-
ease. Figure 1 aims to provide intuition of the qualitative
and quantitative differences in the diffusion of muco-inert
particles of three Class sizes relative to the pore-network
length scales of the mucus gel.
(Significant effort has gone into tuning the surface
chemistry of drug-loaded nanoparticulates for mucosal
delivery, aiming to disrupt the scenario of Figure 1
for muco-inert particles of Class 2 size especially, but
also Class 3. With strong muco-repulsive interactions,
200-300 nm particles that would otherwise have strong
steric interactions with the mucus mesh, instead repel
the mucin molecules, creating larger pores that mini-
mize steric interactions, enhancing their diffusive mo-
bility [2, 3]. Third party crosslinkers (e.g., antibodies)
have been shown to possess the ability to anchor ∼100 nm
nanoparticles to constituents of the mucus polymer net-
work, thereby arresting its motion in a manner that is
equivalent to a knockdown of the effective Brownian dif-
fusivity [4]. We note possibilities of a cocktail surface
chemistry strategy [5], with an exterior muco-inert coat-
ing to promote diffusion through the mucosal barrier that
dissolves on the timescales of passage through the barrier,














tion. This strategy only raises the bar on the diffusive
passage time focus of this review, since one must tune
dissolution times of the exterior coating in mucus to dif-
fusive passage times.)
In this review we discuss the theoretical technologies,
and the experimental technologies for sufficient data ac-
quistion, that are required to quantify and control one-
sided diffusive passage times of drug-loaded carrier par-
ticles through mucosal barriers. In all organs, particles
are deposited at the mucosal interface opposite the ep-
ithelium, and must diffuse through the barrier to the
epithelial interface; thus the terminology used is "one-
sided" diffusive passage time. We emphasize at the out-
set that the required theoretical and experimental tech-
nologies are not yet solved, but they are achievable. We
strive to explain how emerging experimental and theoret-
ical technologies promise to significantly narrow the gaps
in current understanding of the non-Brownian diffusive
processes governing many current drug carrier particles,
and thereby to make strides toward predictive drug par-
ticle engineering design and control.
The present review does not address drug-loaded parti-
cle deposition strategies or the timescales of mucus clear-
ance from a particular organ. For inhaled drug delivery
and lung mucus clearance timescales, we defer to the vast
and active literature on these assessments [6–14].
Herein, we focus on rigorous estimates of one-sided dif-
fusive passage times from particle deposition at the ex-
terior mucus interface through the barrier to the mucus-
epithelium interface. After summarizing the precise con-
trol on passage times afforded by any particle undergoing
simple Brownian motion in mucus, we address the condi-
tions on particles and mucus for which this assumption
is violated. We also assume particle size is sustained
during diffusion in the layer; while we could incorporate
dissolution of the shell radius, the complexities of mucus
viscoelasticity and heterogeneity in depth and biophys-
ical properties, and both size-dependence and chemical
affinity of particles to mucus, are our priority for this
review.
The race between transport through and transport of
the mucosal barrier. For all deposited particles, includ-
ing drug-loaded carrier particles, pathogens, and envi-
ronmental particulates, spanning nanometer to micron
scales, the mucus barrier imposes a limbo status, or de-
lay, during which individual particles must penetrate the
mucus barrier to encounter epithelial cells or vasculature.
This time delay provided by the mucosal barrier gives the
organ time to transport and clear the mucus layer plus
all trapped cargo. Meanwhile, the organ continually re-
plenishes the mucus barrier. For example, the lung pro-
duces on the order of a liter of mucus per day to main-
tain homeostasis [1, 15]. Mucus clearance is achieved
by a combination of coordinated cilia and air drag from
tidal breathing in normal circumstances, each biased to-
ward the trachea, estimated at tens of microns per second
in the small airways, and up to ten times faster in the
upper airways and trachea [cf. [8]]. This experimental
data translates to estimates of clearance times spanning
minutes to hours in the upper airways and up to days
in the central airways in healthy lungs. Thus it is im-
portant to know which branches in the airways a given
inhaler will deposit particles of given sizes, since that sets
the distribution of clearance times that drug particle dif-
fusion through the mucosal barrier must outrace. (An
interesting issue arises in the deep lung which has sig-
nificant pulmonary surfactant. Raesch et al [16] studied
the corona that forms around nanoparticles subjected to
porcine pulmonary surfactant, revealing differences due
to surface chemistries of the particles. Since mucus lay-
ers decrease to negligible in the deep lung, the impact of
surfactant on passage times of particles that reach the
deep lung is a very interesting, and to our knowledge,
unexplored question.)
The mucus escalator picture implies that all trapped
cargo in a local mucus patch is transported together, in-
discriminately. As the conveyor moves, individual par-
ticle mobility will lead to repositioning among all the
cargo, where the key issue for this review is any individ-
ual particle’s position relative to the deposition interface
and epithelium. Cough is a totally different lung airway
clearance mechanism (cf. [17]), with the obvious effect of
violently forcing the mucus layer toward the larynx with
turbulent air drag, including detaching and propelling
droplets of mucus into the air stream toward the trachea.
We do not address the impact of cough on drug particle
delivery. There is a non-intuitive cough effect, consisting
of stress-induced biochemical cascades that trigger ion
transport and thereby stimulate hydration of the airway
[18–22], allowing more efficient transport by cilia and nor-
mal breathing. These effects give a causal explanation for
the persistent cough, day and night, of individuals with
cystic fibrosis.
While particle diffusion in mucus is 3-dimensional,
time to transport from the deposition interface to the ep-
ithelium is the key quantity of interest. While the diffu-
sive mobility of particles in mucus is 3-dimensional, the
only dimension that matters with respect to drug up-
take is motion toward the epithelium. The time it takes
for one-sided diffusion, from the deposition interface to
epithelial tissue, is our definition of the particle passage
time. As noted above, passage times of particles in mu-
cus barriers vary dramatically depending on the diffusion
process of that particle in that mucus. The processes
range from simple Brownian motion for sufficiently small
and non-interacting particles to a wide range of sub-
diffusive, non-Brownian stochastic processes. The inti-
mate interplay between physical and chemical properties
of particles and mucus, their impact on particle passage
times, and the technologies that are necessary to engi-
neer predictive control over drug particle uptake at the
epithelium, are the focus of our review.
The experimental techniques that have been applied
to estimate particle diffusive mobility in mucus are sum-
marized in Section 5, along with the emerging realiza-














size and surface chemistry have such a dramatic im-
pact on diffusive mobility in mucus. The experimen-
tal methods—including Diffusion Chambers, FRAP, and
Particle Tracking—each have limitations that are de-
scribed in Section 5. However, at this junction we want
to call attention to additional concerns that are subtle yet
quite important in the overall goal to estimate particle
diffusive passage times through mucosal barriers in the
lung, sinus, digestive or reproductive tract where the par-
ticle is deposited at one boundary of the mucus barrier
and has to diffuse through to the other boundary with
the epithelium. This physiological "one-sided" diffusive
passage time problem is typically not what is observed
in ex vivo experiments.
If only particles would diffuse "normally", physiologi-
cal versus ex vivo experimental conditions would not mat-
ter. One subtle issue is extrapolation from experimen-
tal observation of particle motion in controlled settings
to the geometry of lung airways or other organs. In dif-
fusion chamber and FRAP experiments (see Section 5),
the diffusion of small molecules and nanoparticles (1-100
nm diameter) are observed in mucus samples from a pa-
tient or assay, revealing a bulk effective diffusivity that
was, surprisingly at the time, only a few times greater
than pure buffer. However, small non-binding molecules
and nanoparticles are mostly diffusing in the pores of
the mucus gel, rarely interacting with the mucin network
of entangled and crosslinked macromolecules. Therefore,
the diffusion is consistent with normal, Brownian mo-
tion, and the concept of an effective diffusion coefficient
for such particles in mucus is valid. This experimental
confirmation has strong implications, because for nor-
mal Brownian motion, one can rigorously extrapolate
from experimental initial and boundary conditions to the
physiological "one-sided diffusion" conditions. The the-
ory and numerical simulations for Brownian motion and
one-sided passage times is presented in Sections 2 and 3,
the ideal scenario.
The effective diffusivity approach to quantify mobility
as a proxy for passage times. Almost all drug delivery
experiments, analyses, and inferences rely on an “effective
diffusivity” for a given particle mobility in mucus, which
either explicitly or implicitly assumes that Brownian mo-
tion is an accurate physical model of particle diffusion
through mucosal barriers. What predictions about pas-
sage times can, and cannot, be inferred from an effective
diffusivity approach? A typical assessment of diffusive
mobility of drug particles is to track particles using mi-
croscopy for a specific timescale, e.g., one second, and to
estimate the effective diffusivity of that particle in that
mucus sample for that timescale, typically one second.
Effective diffusivity breaks down for sufficiently large
particles because of steric hindrance with, electrostatic
and binding interactions with, viscoelastic properties of,
and spatial heterogeneity of, the mucus barrier. The
ability to extrapolate beyond the timescale of experi-
mental observations is based on the fact that effective
diffusivity for simple Brownian diffusion (explained and
illustrated in Section 2) is independent of the observa-
tional timescale chosen: one second, one minute, or one
hour. Sufficiently small molecules, nanoparticles, anti-
bodies, and viruses (except those that become directly
or indirectly crosslinked to the mucus mesh) diffuse nor-
mally through the pores of the mucus mesh, which by
volume constitute 90-98%, with minimal hindrance due
to the 2-10% volume of the large molecule network. How-
ever, particles above ∼200 nm in diameter typically do
not exhibit normal Brownian motion, and the degree of
departure from normal Brownian motion of any given
particle in mucus depends on a multitude of health fac-
tors that influence the pore size distribution within the
mucin molecular mesh as well as the attractive versus
repulsive interactions between the mucin mesh, and par-
ticle size which determines whether the particle samples
some or all entropic fluctuations of the mesh. For par-
ticles comparable in size to the local pore scales, equiv-
alently the local length scales of the mucin-dominated
mesh, steric interactions with the molecular mesh domi-
nate mobility and change the qualitative character of the
position increments of the particles. The entropic fluc-
tuations of the mesh drive particle motion, so one still
observes "movement" but it is strongly hindered relative
to smaller particles that rarely encounter the molecular
mesh.
Furthermore, surface chemistry of particles compara-
ble in size, or larger than, the network mesh scales,
becomes an important factor in mobility. This intu-
itive concept has been explored widely in engineering
of surface-modified drug carrier particles that are muco-
adhesive versus muco-repulsive, aiming toward prolonged
versus shortened passage times through mucus barri-
ers; we revisit these issues below. For particles much
larger than the local mesh scales, elasticity of the mucus
network strongly influences particle motion and induces
clear departure from simple Brownian motion. Particle
increments locally strain the mesh across all length scales
probed by the particle, the strained mesh responds, at-
tempting to relax (reverse the strain) and return to equi-
librium, introducing negative correlations in the incre-
ments over the time scales of elastic relaxation probed by
the particle size. If sufficiently large particles have "neu-
tral" affinity to the network, then the observed displace-
ments versus lag time, when transformed to frequency
space, yield the viscous (loss) and elastic (storage) mod-
uli of the mucus sample; this is indeed the basis of pas-
sive particle tracking microrheology that was introduced
in the mid-1990s [23–27]. The microrheology reviews by
Waigh [28, 29], separated by a decade, are highly recom-
mended.
During the development of passive particle tracking
microrheology, explorations of biomaterials such as en-
tangled and crosslinked F-actin solutions led to impor-
tant limitations on the ability to infer linear viscoelastic
moduli from particle position time series. The observed
motion of passively diffusing beads within the biomate-














and surface chemistry relative to the length scales and
chemical properties of the mesh created by the entangled
/ crosslinked biomolecules; cf. [30]. These and related
studies were critical for microrheology, since they shed
light on the myriad factors that violate the generalized
Stokes-Einstein relation, and thereby tracked particle
time series do not yield the linear viscoelastic moduli of
the biological material being studied. These observations
compelled advances in theoretical microrheology in order
to faithfully interpret experimental data, with particle
size used to probe the length scales of the macromolecular
mesh and the viscosity of the fluids filling the pores, par-
ticle surface chemistry used to probe affinity and phobic-
ity of biomolecules relative to particle surface treatments,
and multiple particle tracking (two-bead microrheology)
used to screen particle-fluid chemical interactions and in-
fer viscoelastic properties of the medium at intermediate
length scales between particles. In Ref. [30], microbeads
of varying diameter and surface treatment were compared
in identical F-actin solutions, including bovine albumin
coated, polyethelene-glycol (PEG) coated, and uncoated
carboxylated microbeads.
All of these findings shed light on the critical factors
influencing how foreign particles diffuse within mucus:
small and large particles relative to the pore scales of
the mucus molecular mesh, and particles that match the
dominant mesh scales, all experience completely different
diffusive motion, with only sufficiently small, non-bound
particles exhibiting simple Brownian motion. Likewise,
particles that have neutral, attractive, and repulsive in-
teractions, especially those with diameters at the dom-
inant mesh scales or larger, experience completely dif-
ferent diffusive motion. Furthermore, particles at or
larger than the mucus mesh scales exhibit transient, sub-
diffusive motion, converging to normal diffusive behav-
ior only at observation lag times exceeding the longest
timescales of memory of the mucus sample (rarely ob-
served). The reviews by Ribbeck and collaborators
[31, 32] give an excellent treatment of the remarkable
diversity of particle mobility in mucin solutions. For mi-
crorheology, these lessons reveal that one can make huge,
orders of magnitude, errors in inference of viscoelastic
moduli with particle tracking by failure to select the right
particle size and surface chemistry.
For particle drug delivery, the “correct” linear vis-
coelastic moduli of the mucosal barrier is irrelevant; the
critical issue is the ability to control one-sided passage
times from the particle deposition interface through the
mucus layer to the epithelium. The particle size and sur-
face chemistry lessons from particle tracking in soft bio-
materials were immediately adopted in mucosal drug de-
livery, with two diametrically opposed strategies: muco-
adhesive and muco-repulsive surface chemistry. When
molecules with a binding affinity to the mucus mesh
are tightly bound to the surface of drug particles, the
particles are muco-adhesive, forcing prolonged passage
times. The aim is to provide an extended time release
of drugs within the particles, during which the particles
slowly release their drug payload. However, this strat-
egy is fraught with the high likelihood of drug particle
clearance from the protected organ, with negative con-
sequences, e.g., in inhaled drug delivery for asthma (im-
mune suppression in the stomach instead of the lung)
[33], cf. [34]. Surface chemistries such as polyethelene-
glycol (PEG) have been shown to be muco-repulsive, with
the ability to tune the particle size, as well as molecular
weight and surface density of PEG, to control nanoparti-
cle diffusion in mucus from diverse organs and mammals
[35].
The mucus gel also utilizes a backup defense mecha-
nism with active (i.e., highly mobile) binding or crosslink-
ing agents, antibodies, that transiently bind to both the
perceived invasive species and the mucus macromolecular
mesh. The role played by antibodies in mucus has been
the focus of the Lai lab at UNC for several years [36–
39] for diverse applications including but not restricted
to drug delivery. These small molecule anchors typically
possess a weak affinity for the mucus microstructure so
that their mobility in mucus is only slightly reduced.
However, with a slightly stronger affinity to any invasive
inhaled species (pathogens or particulates) in mucus, and
the ability for many molecular anchors to crosslink to the
invasive species and the mucus mesh, natural and engi-
neered antibodies have the capacity to dramatically, and
rapidly, decrease mobility and thereby increase the pas-
sage times of the invasive species well beyond the time
window for mucus clearance [34, 35].
For particles that are larger than lung mucus network
length scales, e.g., 500nm and 1 micron diameter beads,
strongly non-Brownian, sub-diffusive particle motion is
detected over a wide range of lag times (cf. [40]). This
sub-diffusive behavior will persist up to the longest elas-
tic memory timescales of the local network surrounding
the particle, which typically exceed the total observation
times of particle tracking. For such particles, surface
treatment (attractive or repulsive to the mucus network)
perturbs the particle motion, thus perturbs the inference
of microrheology of the mucus sample if that was the
purpose of particle tracking. However, for drug delivery
purposes, inference of mucus rheology is not the goal; sur-
face treatment of drug particles is a way to perturb mo-
bility through electrostatic or binding interactions with
the mucus network, and thereby influence passage times.
This strategy is far more powerful for diffusion in vis-
coelastic media than simple viscous fluids precisely be-
cause passage times for transient sub-diffusive motion
scale completely differently than simple diffusion. E.g.,
doubling effective diffusivity for Brownian motion leads
to halving of the mean passage time through a given layer
depth; changes in transient sub-diffusive motion can have
a strongly nonlinear impact on passage times, inducing
orders of magnitude changes rather than multiplicative
factors (cf. [40]), discussed in more detail in the theoret-
ical Sections below.
The timescales of memory in particle fluctuations are














placements (MSD) versus lag time (time between particle
position observations). MSD is the most-used summary
statistic for diffusive mobility, including the drug delivery
literature. Tracked particles above ∼ 200nm in diameter
are typically sub-diffusive (i.e., the MSD does not scale
linearly with lag time) for lag times up to the longest
memory timescale of the mucus network. The mem-
ory timescales of mucus, even in the equilibrium state
of particle tracking experiments, are at least minutes,
and typically hours or longer, far beyond the experimen-
tal timescales of particle tracking. The ability to assess
the longest timescale of memory in mucus is an open
problem, even if the mucus sample is homogeneous. Fur-
thermore, if the passage time of a drug particle exceeds
the mucus memory timescales, then there is a transition
from sub-diffusive scaling to normal diffusion. There is
no theory for passage times of transient sub-diffusive be-
havior, and no theory for passage times in heterogeneous
viscoelastic media, as discussed later. This has many pro-
found consequences, discussed throughout this review,
with the upshot being that it is impossible to extrap-
olate from existing experimental data to passage times
for controlled drug delivery. Prospects to overcome these
hurdles are likewise addressed below.
Leading researchers in drug delivery make a rational
compromise, giving up the ideal goal of accurate assess-
ments of passage times for drug carrier particles in mu-
cus, instead choosing a fixed timescale well within ex-
perimental capabilities, e.g., 1 s, and assessing mobility
exclusively on that timescale, or lag time. This approach
gives qualitative assessments, in particular, relative mo-
bilities among candidate drug carrier particles. But it
does not give quantitative assessments. To get a sense of
the limitation of measuring mobility for a fixed lag time,
consider the MSD of a tracked microbead in mucus. Due
to viscoelasticity, the MSD is sub-linear, and lies below
the linear MSD of normal diffusion for observational lag
times up to 30 seconds or 1 minute, which is a typical du-
ration for microbead particle tracking [40]. This means
that fits over a chosen lag time to an "effective diffu-
sivity", i.e., a linear fit to a sub-linear MSD curve, will
give a different line with a different slope (and thus a
different inferred diffusivity) for every lag time! While it
is perfectly acceptable to compare relative mobilities via
an effective diffusion coefficient for a chosen timescale,
say 1 s, one cannot extrapolate from effective diffusivity
over that timescale to any other timescale, and especially
not to passage times, even if the mucus barrier was per-
fectly homogeneous in physical properties (rheology) and
in layer thickness.
The power to extrapolate, from a carefully designed
experimental dataset to predictive engineering control of
particle passage times in mucosal barriers, is made possi-
ble by the scaling laws of normal diffusion and Brownian
motion, embodied in the Stokes-Einstein relation recalled
in Sections 2, 4 below. In the remainder of this review,
we first discuss the ideal conditions under which this is
a valid assumption, followed by the long list of assump-
tions that are violated for drug particles in mucus, and
the pitfalls (potentially dramatic errors) of any attempt
to invoke an effective diffusivity for estimation of particle
passage times through mucosal layers. We then present
theoretical and computational modeling approaches, and
the requisite experiments and data, to overcome each lim-
itation and pitfall in the “effective diffusivity approach.”
While not all of these technological solutions, either ex-
perimental or computational, are currently implemented
in drug particle design and delivery, we review progress
that has been made, as well as further progress on the
horizon to overcome remaining hurdles. At the very least,
this review outlines a strategy toward increased certainty
in the design and control of drug particle delivery, with
the caveat that some remaining hurdles represent signif-
icant challenges, experimentally and theoretically.
Why not eschew theory and measure passage times
directly? For anomalous sub-diffusion of 200 nm and
larger particles in mucus, little if anything is known about
first passage times, or about how passage times scale with
layer depth, and there is no theory that relates free diffu-
sion to one-sided diffusion with reflection at the deposi-
tion interface. An empirical approach to drug particle de-
sign would be to simply eschew theory and directly mea-
sure passage times in mucus layers. The experimental
technologies, time, and cost required for sufficiently many
observations to infer a reliable one-sided passage time
distribution, even for a given particle in a specific mucus
sample of a fixed layer thickness, are prohibitive. The
experimental limitations are, first and foremost, techno-
logical. Very few, if any, labs do particle tracking in a
physiological geometry; e.g., depositing particles at one
mucus layer interface and tracking their diffusion through
the layer to the opposing interface. Furthermore, most
labs only have 2D particle tracking capabilities, which
only provides particle position time series in a focal plane,
parallel to the plates that bound the sample; this limits
observations of particles within a focal plane. As with
flow of mucus along the airway, the sinus, digestive or
reproductive tract, the measurement of interest for drug
delivery is movement in the direction orthogonal to clear-
ance; experimentally, that means through all focal planes
from the top interface to a chosen depth. Thus, 3D par-
ticle tracking is essential to any empirical approach to
measure passage times.
Piezoelectric stages and emerging light sheet mi-
croscopy allow, in principle, 3D particle tracking (by
a rapid scan of focal planes). But 3D tracking gen-
erates huge video data files, 100s of gigabytes to ter-
abytes depending on the number of particles and the
duration required to observe passage through prescribed
layer depths of 10-100 microns. For inhaled lung deliv-
ery, one can use human bronchial epithelial (HBE) cell
cultures, place fluorescent particles at the air-mucus in-
terface, and then track them until they reach the epithe-
lial layer using 3D microscopy. This strategy is conceiv-
able, but has not been carried out to our knowledge for














Lung: central airway 10-20 µm
Lung: upper airway 50-100 µm
GI tract: stomach 40-450 µm
GI tract: ilium 10 µm
GI tract: colon 110-160 µm
TABLE I. Estimated depth of mucus barriers for various or-
gans [41, 42].
and the time that would be required. Whether one-sided
sub-diffusive transport in a cylinder geometry is equiv-
alent to an annular geometry of the airway is another
interesting question.
Thus one is faced with the following scenario. Ex-
perimental measurements of particle diffusive mobility
in stationary mucus samples of sufficient volume are re-
quired to get particle position time series for sufficiently
long timescales. Then one has to extrapolate from the
particle tracking data to one-sided passage time distri-
butions versus mucus depth. Finally, one must perform
these 3D experiments, record and analyze the particle
tracking data versus particle control parameters, diame-
ter and surface chemistry. Even if one has the resources
to perform all of these experiments, convert the particle
tracking video data to particle position time series, and
analyze the data: is this sufficient to extrapolate and es-
timate particle passage time distributions versus mucosal
layer depths (see Table I). Furthermore, do experiments
and passage time estimates for one organ mucus sam-
ple apply to the same organ but different mucus sample,
e.g., versus age, disease and disease progression of the in-
dividual? How do the passage time estimates scale with
particle diameter or mucus layer depth? Can one extrap-
olate across different particle surface chemistries?
Under ideal circumstances, the answer to all of the
above questions is affirmative. The ideal assumptions
are: mucus is a homogeneous, viscous fluid with a known
viscosity (e.g., 10-100 times more viscous than water);
and the diffusing particle is a passive tracer that moves
solely due to entropic fluctuations of the simple fluid.
For any interaction between the particle and fluid that
does not corrupt the Brownian nature of particle diffu-
sion, then there is an effective diffusivity. Under these
assumptions, since exact scaling laws exist, one does not
have to perform experiments or numerical simulations of
passage times for all particle sizes and mucus viscosities
and layer thicknesses. In fact, one does not have to ob-
serve even one passage time of one particle; the entire
distribution of passage times is known for any particle
diameter, fluid viscosity and thickness of the layer. This
will be presented and illustrated in Section 2, 3. We
then walk through evaluations of passage times as each
of these idealized assumptions are relaxed in light of what
we know about drug particles, human organ mucus, and
particle-mucus interactions.
Recapitulation of factors that violate the ideal scenario
with full control over one-sided passage times of particles
through mucosal organ barriers. Airway, sinus, cervical,
and intestinal mucus is not a simple viscous fluid. Mucus
is a viscoelastic hydrogel, consisting of a mixture of wa-
ter, salts, proteins, immune response agents such as an-
tibodies and bacteriophages, DNA from dead cells, and
a spectrum of mucin macromolecules. Mucins are large
molecular weight glycoproteins with remarkable struc-
ture, including interspersed domains of different scales
and charge density (cf. [7]) that convey the functionality
of the mucosal barrier. Mucus forms a crosslinked, en-
tangled, heterogeneous network, creating a distribution
of fluid-filled pores ranging in size from 100 nm to 500 nm
[41, 43, 44]. Dedicated experimental studies are required
to identify the pore size distribution for a given mucus
sample. The mucus pore size distribution has dramatic
implications for size-dependent particle diffusive mobil-
ity, as illustrated in Figure 1 and discussed above. Parti-
cles much smaller than the local pore scales rarely inter-
act with the mucus mesh network, and typically diffuse
normally with diffusivity determined by the local fluid
viscosity and particle diameter. This explains why small
molecules and 50 nm nanoparticles and 100 nm viruses
in diffusion chambers with mucus that has ∼200-300 nm
mean pore diameter exhibit simple Brownian motion.
There is further evidence that the local fluid viscosity
within pores is heterogeneous, owing possibly to density
variations in small proteins or weak particle interactions
with the local network that can be modeled as a local
effective viscosity. We discuss the impact of viscous het-
erogeneity on Brownian diffusion and passage times in
Section 3, 4.
As discussed above, particles with diameter sufficiently
large (typically above 200 nm) relative to the length
scales of the mucin network, if they have neutral inter-
actions with the network, exhibit correlated fluctuations
and sub-diffusive MSD scaling over long timescales that
reveal the local, frequency-dependent, viscous and elas-
tic moduli of the mucus gel. This scenario is the funda-
mental basis of passive particle tracking microrheology
— to convert entropic fluctuations of passive microbeads
to equilibrium viscoelastic moduli via the Generalized
Stokes-Einstein Relation (GSER, cf. [23, 45]), which we
recall and discuss in Section 3. If sufficiently large par-
ticles have attractive and/or repulsive interactions with
the mucus network, their motion is some perturbation
of neutral particle motion, which will typically not obey
the GSER scaling behavior. In all cases, the particle dif-
fusive behavior is not simple Brownian motion, and the
only strategy for estimation of passage times is based on
modeling and simulation. Such a strategy requires so-
phisticated modeling of transient, sub-diffusive processes
together with significant experimental and theoretical
challenges to identify the timescales of memory due to
elasticity of the network (cf. [46–51]).
A higher level design task, our penultimate goal in this
review, is to not only insure drug penetration through the
mucus barrier with quantification of the inherent uncer-
tainty, but to control the passage time distributions, i.e.,














We summarize the requisite technologies (experimental
and theoretical) to achieve such a high-level design, both
progress and challenges associated with each technology,
toward a capability to dictate the dynamic schedule of
drug dosage to the airway epithelium, including an as-
sessment of the factors governing variability and uncer-
tainty even if the full design task is fulfilled.
2. THE IDEAL SCENARIO WITH PRECISE
CONTROL OVER INHALED PARTICLE
PASSAGE TIMES THROUGH MUCUS
BARRIERS
Assume a mucus layer of uniform thickness, L, uniform
viscosity η, and particles of radius r. In this Section, we
assume the simplest scenario, namely that particles un-
dergo simple Brownian motion (a precise mathematical
definition is presented in Section 2 2.1). We treat the
mucus deposition interface as a reflecting boundary; par-
ticles start at the deposition interface, with movement
only allowed into the mucus layer. The mucus-epithelium
interface is modeled as an absorbing boundary; when a
particle first encounters this boundary, the total elapsed
time is recorded and the time series is terminated. A
sample particle trajectory is shown in Figure 2.
Many such particle trajectories are simulated, and the
time it takes to pass from entry point to exit point, the
one-sided particle passage time, is recorded for each sim-
ulated particle. In Figure 3, a histogram of passage times
from 10,000 particle simulations is shown, along with the
exact values of the probability density function and mean
first passage time given in Section 3.
A natural question arises at this point: What are
the first passage time distributions and mean passage
times for other particle radii r, mucus viscosities η and
thicknesses L? We can, of course, compute the an-
swers across the full 3-parameter space (r, η, L) for a rel-
evant range of each parameter, just like we generated
the passage time histogram in Figure 3 for the choice
(r, η, L) = (0.5, 2.34× 10−8, 5). Figures 4 and 5 illustrate
the brute force results of direct simulations for (r, η, L) =
(0.5, 2.34× 10−8, L) for mucus depths L = 1, 2, 10µm,
and (r, η, L) = (r, 2.34× 10−8, 5) for r = 0.1R, 0.2R,R.
Figures 4 and 5 correspond to sparse data along two
line segments in a 3-dimensional parallelopiped, indicat-
ing how cumbersome it is to not only generate the data
over a large parameter space, but then one has to mine
the dataset for meaningful information. We shall come
back to this onerous task when we discuss the realities of
particles diffusing in mucus. Meanwhile, if one looks at
the mean first passage times (MFPT) in Figures 4 and 5,
a striking realization is evident: the MFPT scales linearly
with r and quadratically with L. If we had computed the
analog of Figures 4 and 5 for η, we would observe a linear
scaling of MFPT with η.
Here is where a rigorous theory for the ideal scenario
not only confirms these observations, but generalizes
them across the entire 3-parameter space (r, η, L)! The
exact formula for the MFPT of the one-sided diffusion
of Brownian particles of radius r in a layer of uniform
viscosity η and uniform depth L, starting at a reflecting
boundary z = 0 and diffusing until hitting an absorbing
boundary z = L, is








〈T 〉 = 3π
EB
ηrL2. (2.2)
where EB = kBTK ≈ 4.1 pNnm (at 25 ◦C) is the natural
energy scaling factor for molecular scale systems. There-
fore we confirm that the MFPT scales linearly with r and
η and quadratically with L, and given the precise parti-
cle size, mucus viscosity and thickness, the exact value of
MFPT is known. Furthermore, there is an exact formula
for the entire passage time distribution, given in Section
3, which is an infinite series but it can be calculated nu-
merically to arbitrary precision, as illustrated in Figures
3 and 4.
With these precise results in hand, we return to the de-
sign goals for inhaled drug particle delivery, and assume
the ideal scenario is applicable. For sufficiently small
molecules and nanoparticles that do not interact with
the mucus network in any significant way, their diffusion
is normal with an effective diffusivity D = EB/(6πηr),
the celebrated Stokes-Einstein relation. If particles are
polydisperse with a known distribution of radii r, it is
straightforward to generate the full passage time distri-
bution and MFPT. In Section 3, we discuss analogous
scenarios in which the layer thickness is non-uniform and
the viscosity is heterogeneous, and show how the the-
ory of Brownian motion can be extended, tediously yet
straightforwardly, to rigorously compute the full passage
time distributions and MFPTs for polydisperse particles
in heterogeneous viscous fluids of variable thickness. This
exercise illustrates the power of the direct application of
the scaling laws for Brownian motion. For application
of the fundamental theory to drug particle design, one
designs the particle radius distribution and wants to pre-
scribe the passage time distribution. The only unknowns
that we need are the mucus viscosity distribution and
the mucus thickness profile in the airways of deposition.
As stated at the outset, we defer to other technologies to
estimate the layer thickness profile; heterogeneous thick-
ness profiles are addressed in Section 2.2 for this ideal
scenario. Thus, our only remaining task is to infer the
mucus viscosity distribution, an inverse problem, whose
solution for viscous fluids is straightforward via particle
tracking. One first must distribute particles of any fixed
radius randomly throughout the mucus sample, and use
particle tracking technology to get their position time
series.
For each particle position time series, in a locally uni-
























The increment statistics of each particle will give the
local diffusivity D = EB/(6πηr) of the spatial mucus
environment they are sampling. Since r, EB are known,
one determines η at the random experimental sampling
of the mucus volume. The only caveat is that the length
scales of heterogeneity in viscosity should be larger than
the distance traversed by each tracked particle. One can
confirm this caveat by looking at the histograms of incre-
ments to confirm they are Gaussian and not a mixture of
Gaussians (which would indicate the particle increments
are from distinct viscosities); if necessary, one can reduce
the observation time of each particle to resolve finer spa-
tial scales of viscous heterogeneity. This adaptation to
smaller observation times is possible for normal Brown-
ian motion, with the only price being a larger error bar in
the inferred diffusivity; for non-Brownian motion, fewer
observations, i.e., shorter increment lag times of observed
particles, severely limits the ability to perform model se-
lection among all candidate non-Brownian, sub-diffusive
processes.
Since exact relationships are known for all parame-
ters of interest, all problems of this nature are precisely
connected to one another. That is, one can normalize
the probability density functions and time values by the
mean first passage time, T , such that all of these curves
collapse on each other, shown in Figure 6, below. Given
the dimensionless curve shown in Figure 6, we can rescale
the curve to represent the probability density function
when we know the values of the parameters of interest
(i.e., D and L).
2.1. First passage time across a viscous mucus
barrier
The development of first passage time theory for
stochastic physics of submicron biological systems has
advanced significantly in the last few decades [52–61].
The strength of the theory is its ability to explore how
thermal fluctuations, chemical interactions, and mechan-
ical forces on a particle play out in specific scenarios that
include the complex geometries typical of living systems.
For example, the first passage time for a transcription
factor to locate a specific sequence of DNA involves ran-
dom motion within the nucleoplasm, interspersed with
random motion along DNA filaments. The combination
of the two phases of motion substantially speeds up the
first passage time [60].
In this section, we formulate penetration of a mucosal
barrier by drug particles as a first passage time problem.
For completeness, we include the basic formulation of a

















FIG. 2. A sample Brownian particle trajectory in a layer of
uniform depth L = 5 µm and viscosity η = 25 times that of
water, 2.34× 10−8 µm2 s−1, with a time step, τ , of 1/60 s. As
the particle of radius r = 0.5 µm undergoes Brownian mo-
tion through the layer, it stays near the presumed air-fluid
interface at early times, returning to and reflecting from the
upper boundary. Gradually, the particle moves away from the
boundary and eventually is absorbed at the lower boundary
at T = 601 s for this simulation.


























Exact Mean First Passage Time
FIG. 3. Probability Density histogram of passage times for
particle simulations described in Figure 2, together with the
exact PDF and mean first passage time. The PDF is closely
approximated by a lognormal distribution.
Let X(t) be the distance of a given particle undergoing
Brownian motion from the airway lumen. Let the ran-
dom variable τ be the first passage time, defined as the
first time at which the particle reaches the epithelium
at X(t) = L (in mathematical terms the definition is







































First Passage Time (s)
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FIG. 4. First passage time distributions for different values
of the layer thickness, L. The means for the distributions are
indicated by the dots below each, and they demonstrate that
the times it takes to pass through the layer increases as a


























First Passage Time (s)
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FIG. 5. First passage time distributions as a function of par-
ticle radius, r. The mean first passage times have a linear
relationship with both r and η.






, 0 < x < L, (2.4)
∂p
∂x
= 0, x = 0, (2.5)
p(L, x0, t) = 0, t > 0, (2.6)
p(x, x0, 0) = δ(x− x0). (2.7)
The solution to this equation can be regarded in two
equivalent ways. First, p(·) can be viewed as the nor-
malized concentration of a drug particle released instan-
taneously at a distance x0 from the airway lumen and
absorbed at the epithelium. Second, from the perspec-























FIG. 6. A master curve demonstrating the ability to scale first
passage time distributions by L and D such that all curves
are equivalent.























Simulation: L = 7 m, D = 0.031
Scaled PDF
FIG. 7. The dimensionless PDF in Figure 6 scaled to repre-
sent specific values of L and D.
tive a single drug particle, we have
p(x, x0, t)dx =
Prob {x < X(t) < x+ dx, t < τ | X(0) = x0} . (2.8)
Given the solution to (2.4), the first passage time den-
sity is derived as follows. The probability the particle has
not yet exited the layer at time t is called the survival
probability and is given by
S(t) = Prob[t < τ | x0] =
∫ L
0














The first passage time distribution is then



















where the last two lines made use of (2.4).
The FPT can be written in two equivalent forms, both
of which are infinite series rather than an algebraic for-
mula. Nonetheless, the terms of the series converge under
most circumstances so that the series can be truncated to
obtain an approximation with any desired accuracy. The
truncation error gets smaller as more terms are included
in the series. There are two different series representa-
tions [63]: one that converges quickly for short times and
the other for large times. For fast convergence at small
times (t < L2/(2D)), the first passage time density is





















For fast convergence at large times (t > L
2
2D ), the first
passage time density is















At x0 = 0, the formulae for the first passage time density
and cumulative distribution (denoted as F (t)) simplify
to











(−1)n(2n+ 1)e−(2n+1)2 T2t ,
(2.14)































In practice, either expression can be used, except for ex-
treme values of very large or vary small values of t.
An explicit solution to (2.4) can only be found in lim-
ited circumstances. A simpler equation for the mean first
passage time is available [62, 64], which allows us to ex-
tend our understanding, for example, to the case where
the mucus layer has variable depth and/or viscosity. De-
note the mean first passage time as T (r), where r is the
initial position. One can show that the MFPT satisfies
D∇2T = −1, r ∈ (0, L)× R2 (2.18)
∂T
∂x
= 0, x = 0 (2.19)
T = 0, x = L. (2.20)





At x0 = 0, the above formula simplifies to (2.1).
To illustrate how the MFPT alone can be useful, we
examine the effect of variability in the depth of the mucus
barrier.
2.2. Heterogeneity in the layer depth
It is highly idealized to assume that the mucus bar-
rier has a uniform depth across the entire surface of the
organ. As we show in this section, the effect of vari-
able depth on the MFPT is not as simple as one might
expect. Suppose we compare the MFPT for two hypo-
thetical scenarios: a constant depth layer and a variable
depth layer, each having the same average depth. The
following result tells us that even though the two lay-
ers contain the same volume of mucus, it takes longer
on average for a particle to penetrate the variable depth
layer. While some particles in the variable depth layer
start closer to the epithelium and take less time to tra-
verse the mucus barrier, an equal fraction of particles
start farther away and require more time. Recall that
the MFPT scales with the square of the depth L. Hence,
the slow down for the fraction that start farther from the
epithelium will be comparatively larger than the speed
up for the fraction that start closer. This observation
follows the general rule that diffusive transport is more
efficient over short distances than long distances [65] for
normal Brownian motion; for non-Brownian, transient,














Assume that the layer thickness is a function of y, the
distance along the centerline of the airway. For simplicity,
assume that the depth is a periodic function L( yλ ) > 0,









If we assume that we have a slowly-varying depth then
the MFPT is approximately





, λ≫ 〈L〉 . (2.23)








Notice that this result is not the one we might expect
from a naive guess, namely 〈T 〉 ∼ 〈L〉2 /(2D). Indeed,
we can write L( yλ ) = 〈L〉+ f(y) where f(y) is a periodic


















depends on the maximum am-
plitude. For example, if f(y) = A sin(2πy/λ), where





3. HETEROGENEITY IN THE VISCOSITY OF
A MUCUS BARRIER
Variation in the viscosity within the pores of a mucus
barrier, relevant to sufficiently small particle diffusion,
arises due to local density of proteins and other small
molecules. The pore viscosity is potentially stratified
from the mucus deposition interface to the epithelium,
arising perhaps from mucus production in the epithelium
or active forcing at the deposition or epithelial interface.
The principal result of this section is that the MFPT
across a variable viscosity mucus layer is roughly equiv-
alent to a homogeneous layer with a spatially averaged
viscosity. For a stratified layer, the MFPT is simply the
sum of all the MFPTs through each sublayer, and the rel-
ative order of each layer does not affect the MFPT. Nei-
ther of these results is known to generalize to viscoelastic
diffusion.
Suppose that the viscosity depends on the position





There are multiple formulations for stochastic models of
particle motion with variable diffusivity, often refered to
as multiplicative noise. Physical considerations are re-
quired to resolve the appropriate model. The most com-
mon approach is to require the model to satisfy a detailed
balance constraint, which ensures that the particle distri-
bution approaches a steady state that is consistent with
the Boltzmann distribution [66, 67]. This is the correct
approach, provided that there are no active (i.e., energy
consuming) processes that establish concentration gradi-
ents under steady state conditions. Particle diffusion in
a Newtonian fluid with variable viscosity is governed by
∂
∂t
p(r, t | r0) = ∇ · (D(r)∇p), r ∈ (0, L)× R, (3.2)
∂p
∂x
= 0, x = L, (3.3)
p = 0, x = 0, (3.4)
p(r, 0 | r0) = δ(r− r0). (3.5)
To derive a stochastic differential equation that can be




p(r, t | r0) = −∇ · (p∇D) +∇2(D(r)p). (3.6)




where dW is the standard Wiener process [62]. The sim-
plest numerical scheme is Euler’s method,




where tn = n∆t and Z(tn) is a normal random variable
with mean zero and unit variance. An efficient Euler-like
scheme for simulating the process near reflecting bound-
aries is given by [68]. We want to examine two scenarios:
viscosity periodic in y and viscosity periodic in x. For
simplicity, we ignore the z direction.
3.0.1. Depth-wise variable viscosity
The extension of the MFPT equation (2.18) to variable
























If D(x) is piecewise constant, then the MFPT is simply














3.0.2. Variable viscosity along the centerline axis of an
airway
Suppose that D(r) = D(y/λ), with λ > 0, is a λ peri-
odic function. Variation of viscosity in the y coordinate





















(0, y) = T (L, y) = 0, (3.14)
T (x, y) = T (x, y + λ). (3.15)
Both T and D are strictly positive, and we can assume
that the two functions are anti-correlated in y, meaning
that when D increases, we can expect a corresponding

























(One can show that this is asymptotically accurate for
both λ ≪ L and λ ≫ L.) By averaging (3.13)-(3.15)
with respect to a uniformly distributed initial position
y0 and setting x0 = 0, we obtain

















Hence, the MFPT is proportional to the averaged viscos-
ity.
4. FIRST PASSAGE TIMES ACROSS A
VISCOELASTIC MUCUS BARRIER
Unlike particles below 100 nm diameter exhibiting vis-
cous dynamics, particles of diameter ∼200 nm or larger
interact with the mucosal mesh structure, thereby ex-
hibiting dynamical “memory” that cannot be explained
by Brownian motion alone. That is, if Xt is the position
of the particle at time t, Brownian dynamics would pre-
dict that the mean squared displacement (MSD) of the





However, the MSD of these larger particles is almost al-






for 0 < α < 1 and on some timescale t ∈ (tmin, tmax).
The fundamental laws of motion of such particles are de-
scribed by a Generalized Langevin Equation (GLE) [69],
mẌt = −κXt −
∫ t
−∞
γ(t− s)Ẋs ds+ Ft, (4.3)
wherem is the mass of the particle, Ẍt is its acceleration,
κ is a spring-like potential force, γ(t) is the memory ker-
nel for the frictional force on the velocity Ẋt, and Ft is
the thermal force, a stationary stochastic process satisfy-
ing the Fluctuation-Dissipation theorem [69], such that
its autocorrelation is given by
〈Fs, Fs+t〉 = EBγ(t). (4.4)
While the GLE interprets conveniently as the decompo-
sition of the total force (mẌt) acting on the particle into
potential, frictional, and thermal forces, it can be rig-
orously derived from the Hamiltonian equations of mo-
tion for any particle in a microcanonical physical ensem-
ble [70]. As such, the GLE has often served as a foun-
dational tool for physically valid modeling of viscoelastic
particle dynamics [47, 49–51, 71]. Two GLE models have
proved particularly useful in this respect.
The first assumes a Maxwellian linear viscoelastic
regime [50], wherein the memory kernel γ(t) is composed







exp(−t/τk), τk = τ(K/k)1/α. (4.5)
Assuming a negligible potential force κ = 0, the so-called







tα t ∈ (tmin, tmax)
t otherwise,
(4.6)
where tmin and tmax are functions of τ and K.
The second major GLE model is that of fractional
Brownian motion (fBM), a continuous Gaussian process
with zero mean and covariance function
〈Xs, Xt〉 = (D/2)(|t|α + |s|α − |t− s|α), (4.7)





It can be shown that fBM satisfies a GLE with negligible
potential force κ = 0 and in the “zero-mass limit” m = 0,
with γ(t) ∝ t−α [72].
4.1. Calculation of first passage times
Several analytic results for first passage times have
been derived for fBM [cf. 73] and to a lesser extent, for
GLEs as well [74]. However, almost none of the results we
have surveyed account for the reflecting boundary condi-
tion required here. One notable exception is [75], which
derives the MFPT for an fBM particle, but only when
released far from the airway lumen, x0 ≫ 0. In contrast
to these analytic results, the following method of simu-














cost of computational power and (controllable) approxi-
mation accuracy.
First, we note that the reflecting-boundary process X̃t
corresponding to a general one-dimensional stochastic
process Xt is given by [76]
X̃t = Xt − inf
0≤s≤t
Xs, (4.9)
which only for Brownian motion corresponds to X̃t =
|Xt|. To simulate the reflected process one then employs
a simple numerical discretization scheme [77]
X̃n = Xn − min
0≤j≤n
Xj , (4.10)
where X0, · · · , XN are observations of Xt with fre-
quency ∆t. [77] prove that for fBM, the strong dis-
cretization error is of order ∆tα/2. On the other hand,
both fBM and the Rouse-GLE with zero-mass limit are
stationary-increment processes with closed-form auto-
correlation functions [71], which can be simulated in
O(N logN) operations using the circulant embedding
method of [78, 79]. In the more general setting, the GLE
can be solved explicitly in the Fourier domain:
X(ω) =
1
κ−mω2 + iωγ̂(ω)F (ω), (4.11)
where X(ω) = F{Xt} =
∫∞
−∞




e−iωtγ(t) dt, such that Xt can be simu-
lated approximately using FFT methods. Employing a
similar approach, [51] showed that the MFPT across a
two-sided barrier of the Rouse-GLE (4.5) scales linearly
in the particle radius r, and quadratically in the barrier
depth L, which agrees with the analytic calculation for
Brownian motion with reflecting boundary (2.1).
4.2. Parameter estimation from experimental data
In [46, 47], the two- or three-dimensional trajectory of
the particle Xt is modeled as
Xt = µt+Σ
1/2Zt, (4.12)
where µ is a vector of coordinate-wise linear drifts, Σ is a
variance matrix, and Zt are independent and identically
distributed Gaussian continuous stationary-increments
(CSI) processes, such that their covariance structure is





Both fBM and the Rouse-GLE (4.5) with κ = 0 and
m = 0 [71] are shown to be expressible in this form, with
θ = α and θ = (α, τ,K). Let X = (X0, . . . ,XN ) denote
observations of the particle recorded at regular time in-
tervals of ∆t. Then under model (4.12), the maximum
likelihood estimate of all parameters Θ = (µ,Σ,θ),
Θ̂ = argmax
Θ
p(X | Θ), (4.14)
along with its error bars, can be calculated efficiently
via the methods in [46, 47, 80]. In particular, [47] show
that the generalized Rouse-GLE model provides a much
better fit than fBM to tracer particles in 2.5% wt human
bronchial epithelial (HBE) mucus, reliably detecting tmin,
the transition time from ordinary to sub-diffusive MSD
scaling. However, calibrating the number of modes K
from experimental data remains a computational chal-
lenge, and the experimental timescales thus far offer vir-
tually no information about tmax, the longest timescale of
memory, a fundamental parameter for FPT calculations.
The shortest timescale of memory in HBE mucus, tmin,
is negligible (fractions of a second) for passage time es-
timates, whereas the longest timescale of memory, tmax,
is minutes if not hours, and thereby is critical for pas-
sage time estimates. However, a dedicated experimental
effort to track particles for minutes is required, where
one can expand the lag time between observations but
must track particles far beyond current tracking data.
This will not only require experimental time and cost,
video data storage expense, but also light sheet 3D par-
ticle tracking and automated conversion of video files to
particle time series such as the convolutional neural net
algorithm [81]. Given such 3D time series, methods in
[47] will produce a fully parametrized, generalized Rouse-
GLE model, which can then be simulated to predict phys-
iological passage times versus mucus layer thickness, as
illustrated in [51], assuming mucus viscoelasticity is ho-
mogeneous! Of course, mucus is heterogeneous, so future
prospects to accommodate this reality are presented next.
4.3. Heterogeneous viscoelastic mucus barriers
Obtaining a physically valid description of particle dy-
namics reflecting both (i) a memory component due to
interactions with the mucus network and (ii) the spatial
heterogeneity of said network – is an open modeling chal-
lenge. One possible approach is to couple the GLE (4.3)
with a nonlinear potential force, such that
mẌt = −U ′(Xt)−
∫ t
−∞
γ(t− s)Ẋs ds+ Ft. (4.15)







suggesting that the potential term U(x) can account for
variations in the elasticity and/or mesh size of the mu-
cus network, which affect the particle’s mobility. Euler-
type discretization schemes for (4.16) have been discussed
by [82, 83], although the scaling of these algorithms is














5. EXPERIMENTAL TECHNIQUES TO
QUANTIFY "NANOPARTICLE" TRANSPORT IN
MUCUS
Any mathematical modality and prediction of the
timescales of "nanoparticle" penetration through mu-
cosal barriers critically depends on accurate experimental
measurements of transport properties. Here “nano” refers
to particle scales ranging from nanometers to microns.
This has motivated a number of techniques to assess the
degree to which transport is hindered by the mucus bar-
rier, and furthermore to use these techniques to test par-
ticle design parameters (size and surface chemistry) for
their impact on diffusive transport in mucus. We intro-
duce and briefly describe the most common experimental
techniques used in recent years and their respective ad-
vantages as well as limitations.
5.1. Diffusion chambers
One of the earliest techniques used to quantify the dif-
fusion of small molecules and nanoparticles through mu-
cus was the diffusion chamber [84–88], where a thin layer
of mucus is sandwiched between a donor and an acceptor
compartment (Figure 8.A). The rates with which a par-
ticle or molecule of interest in the donor compartment
can diffuse through the mucus layer into the acceptor
compartment, as a result of the concentration gradient,
can be measured over time. At steady-state flux, an ef-
fective diffusion coefficient D can be calculated from the
concentration profile within the mucus layer [89].
Sinko and coworkers were among the first to use the
diffusion chamber system (Transwell-Snapwell diffusion
chamber apparatus) to study the one-dimensional effec-
tive diffusivity of nanoparticles of various sizes in mucus
[90]. Using reconstituted porcine gastric mucin gel as a
model for human mucus, the group observed a signifi-
cant decrease in diffusive mobility (beyond the expected
scaling with particle size from the Stokes-Einstein rela-
tion), as inferred from measured translocation perme-
ability as the particle size approached 300 nm. Simi-
larly, Sanders and coworkers reported decreasing pene-
tration percentages of carboxylated polystyrene nanopar-
ticles (0.24, 0.022, and 0.0017%) diffusing across a 220 µm
thick cystic fibrosis (CF) sputum layer as the particle size
increased (124, 270, and 560 nm, respectively) [84]. From
these results, the authors concluded that the bulk vis-
coelasticity of the CF sputum effectively limited the dif-
fusion of nanoparticles. To paraphrase, the nanoparticle
diffusion data in CF sputum was violating the Stokes-
Einstein scaling behavior of the diffusion coefficient D
with particle size, from which the authors concluded that
particles in mucus above a certain size, e.g.,200-300 nm,
fail to adhere to normal Brownian motion. These obser-
vations were a few years into the rapidly growing field
of particle-tracking microrheology, where it was widely
observed that particles at or above the lengthscales of
the microstructure in colloids and polymer solutions ex-
hibit non-Brownian, indeed sub-diffusive scaling, which
was consistent with some mechanism of hindered diffu-
sion relative to Brownian motion.
Although the diffusion chamber technique for measur-
ing drug and particle diffusion across mucus barriers is
simple and allows quantification of the effective flux from
which average effective diffusion coefficients can be cal-
culate, there are a number of important limitations. For
example, these measurements are typically taken over
the course of several hours, which limits insights into the
transport behavior over short durations [84]. There are
also experimental setup challenges that can strongly in-
fluence the measurements but are very difficult to control,
such as controlling the thickness of the mucus layer, en-
suring uniformity of the mucus thickness over the entire
surface of the filters, potential blockage of filter pores
by mucins, and alterations in mucus properties during
preparation [91]. Indeed, the diffusion chamber filter is
often able to non-specifically adhere to nanoparticles [84]
and/or allow significant amounts of mucin molecules to
diffuse into either the donor or acceptor compartments,
thereby reducing the barrier properties of the mucus layer
[90]. Finally, diffusion chamber measurements only pro-
vide bulk average estimates of an effective diffusivity.
Thus, such measurements rely on the fundamental as-
sumption of normal Brownian motion (otherwise, there
is no known relation between measured flux and diffu-
sion law parameters such as diffusivity), and further fail
to provide insights into distributions and heterogeneity in
the diffusive mobility of nanoparticles. Both issues con-
found mathematical efforts to predict passage times on
the basis of experimental data, which require one to ac-
curately identify a diffusion process consistent with mea-
sured data, to select among all candidate processes, and
to estimate parameters of the best-fit process. Due to
these significant challenges, many investigators turned
to high-resolution microscopy techniques to characterize
transport through mucus.
5.2. Fluorescence recovery after photobleaching
Fluorescence recovery after photobleaching (FRAP)
has been used to quantify the effective diffusion rates of
proteins, viruses, nanoparticles, and many other macro-
molecules in various biological tissues, including mucus
[91–95]. The basis of FRAP involves using strong fluo-
rescence intensity to effectively photobleach a small de-
fined area within a specimen containing a fluorescent
entity of interest (e.g., a protein), followed by quanti-
fying the recovery of fluorescence into the defined area
over time (Figure 8.B). An effective diffusion coefficient
can be calculated for the molecule of interest, generally
based on the time required to reach 50% recovery of pre-
bleached fluorescence. The immobile fractions can also
be determined based on the ratio of the plateau inten-














tensity in a neighboring non-bleached area [92]. Each
FRAP measurement typically takes a few minutes com-
pared to the multiple hours required with diffusion cham-
bers, and multiple measurements are performed on each
specimen (8-20) to arrive at an average diffusivity mea-
surement. As emphasized throughout this review, for
small molecules and sufficiently small nanoparticles be-
low the length scales of the entangled and crosslinked
mucin network, and that do not bind significantly to the
mucus network, their diffusion is reasonably modeled by
simple Brownian motion, for which an effective diffusivity
is relevant.
The landmark work by the Saltzman and Cone groups
on diffusion in human mid-cycle cervical mucus utilized
FRAP to measure the diffusion coefficients of antibodies
(IgG and IgA) and select capsid viruses (Norwalk and
human papilloma). Prior to their work, the prevailing
dogma was that the bulk viscosity of mucus greatly lim-
ited the diffusion of proteins and viruses across mucus.
The FRAP technique enabled them to discover that both
antibodies and viruses can undergo rapid diffusion in mu-
cus at rates comparable to those in buffer [91, 93]. In a
different study using FRAP, Braeckmans and coworkers
observed rapid and nearly complete fluorescence recov-
ery (> 90%) of different-sized fluorescent labeled dex-
tran (hydrodynamic radii of 9, 15, and 33 nm) in CF
sputum, which further verifies that CF sputum pores are
filled with relatively low viscosity interstitial fluids (only
4- to 6-fold higher viscosity than that of pure water) [92].
In the same study, FRAP was also used to measure the
immobile fractions of 37 and 89 nm polystyrene nanopar-
ticles in CF mucus (38% and 56%, respectively); the au-
thors attributed the high immobile fractions to adhesive
interactions between the hydrophobic domains of mucins
and hydrophobic polystyrene particle surface. More re-
cently, nanoparticle transport in native and highly puri-
fied mucus matrices was assessed in the presence of gu-
luronate oligomers using FRAP. By decreasing the den-
sity of mucin network crosslinks and consequently in-
creasing the network pore size, the authors found that
guluronate oligomers increased mobility of the nanopar-
ticles across mucus layers [95].
As described above, due to its ability to quantify real-
time transport over very small distances and durations
(i.e., high spatiotemporal resolution), FRAP has pro-
vided valuable insights into the effective diffusion of suf-
ficiently small molecules and nanoparticles in mucus. It
is possible to measure spatial variability in transport,
thus heterogeneity in effective diffusivity, by perform-
ing multiple measurements in different regions of a spec-
imen, which represents another improvement over diffu-
sion chamber studies that yield only one measured trans-
port value per specimen. Nevertheless, it is important to
note that each FRAP measurement still represents only
an ensemble-averaged diffusion rate within that region,
and hence fails to provide quantitative insights into the
heterogeneity of transport among different populations
of particles. Insight into heterogeneity is particularly im-
portant for diffusion in heterogeneous media such as mu-
cus, where the same particles can exhibit orders of mag-
nitude variations in diffusion coefficients [96]. Another
concern with FRAP is the high concentration of fluores-
cent particles required within the mucus sample to pro-
duce a bright and uniform fluorescent background [97],
which generally promotes a smooth recovery curve for ac-
curate estimation of diffusion coefficients. At high con-
centrations, nanoparticles can cause mucin fibers to ag-
gregate, resulting in significant microstructural changes
to the mucus mesh, such as increased mesh pore size
[93, 98]. We reiterate that the overall successes in under-
standing diffusive transport in mucus using FRAP are
exclusively for sufficiently small particles, Class 1 in Fig-
ure 1.
5.3. Particle Tracking
To circumvent issues with and limitations of FRAP, re-
searchers are increasingly adopting another microscopy
method, particle tracking (PT), for quantifying trans-
port of drug and gene carrier particles in various tis-
sues, including nanoparticle transport in mucus [3, 34,
35, 44, 99–107]. PT involves capturing videos of nanopar-
ticle diffusion with high frame rates, and subsequently
converting the real-time motion of individual nanopar-
ticles into position time series ("tracks"), from which
data analysis can be performed. If the particles are suf-
ficiently small and their tracks are consistent with Brow-
nian motion, then an effective diffusivity of the mucus
(or any fluid) sample can be inferred, locally from indi-
vidual nanoparticles and volume averaged for an ensem-
ble of particles in any chosen volume that contains the
tracked particles. In order to ensure high fidelity track-
ing of the same nanoparticles, PT is typically performed
with an epifluorescence or confocal microscope equipped
with a high magnification objective (63x or 100x) and a
high-speed camera capable of up to 60 frames per sec-
ond (fps) imaging [108]. Unlike FRAP, PT does not
require high concentrations of nanoparticles in the mu-
cus sample, minimizing concerns with mucus dilution or
mucin bundling and with particle-particle interactions.
The common statistic for PT experiments is the mean-
squared-displacement (MSD) of individual or ensemble-
averaged particle traces (Figure 8.C). The MSD statistic
can be used to quantitatively estimate how far particles
move over given timescales if the particles obey Brownian
motion, as explained in Sections 2 and 3, but only qual-
itative, relative estimates can be inferred from the MSD
statistic for non-Brownian motion [41, 96, 108–110], and
even then, all relative mobilities are restricted to the du-
ration of the particle tracks, which are typically at most
one minute.
There are additional drawbacks and shortcomings of
focusing on MSD to understand particle mobility. First,
the common understanding of MSD scaling (linear, sub-














domains", which eliminates virtually all biologically rel-
evant scenarios. Second, correlations in the increments
of a path can be influenced by a host of factors, and
often several completely different mechanisms can have
the same effect on the "shape" (i.e., scaling) of the MSD
locally and globally versus lag time (time between in-
crements). Third, standard methods for calculating the
MSD (e.g., using overlapping lag times to get enough
data for longer lag times, and estimating particle by a
non-zero mean of the increments, then subtraction of
drift from the increments) impose correlations that skew
the MSD estimate [46, 47].
The modern theory of statistical physics for micron
scale biological systems has largely eliminated the need
for the traditional MSD-based analysis. There is a wide
range of mechanistic stochastic models that describe a
particle and the factors within the physical system that
influence its motion. Moreover, there is a highly de-
veloped mathematical framework for formulating new
stochastic models or revising existing ones as our un-
derstanding evolves [62, 111, 112]. A stochastic model
can be used to predict particle mobility in realistic bi-
ological contexts, including boundary effects, with first
passage time theory [60, 64, 112]. These advances were
illustrated in Section 3. Modern statistical methods can
be used in conjunction with a stochastic model to analyze
particle tracking data in order to extract relevant param-
eter values and quantitatively compare competing models
[46, 47]. These advances and remaining challenges were
addressed in Section 4.
In one of the first PT experiments studying transport
of nanoparticles in mucus, Dawson and co-workers mea-
sured the movements of carboxylate- and amine-modified
polystyrene nanoparticles sized 100-500 nm in sputum
obtained from patients with CF [107]. The authors used
the PT data to calculate effective diffusion coefficients
for these nanoparticles (notwithstanding the strong like-
lihood that many of the particles were undergoing non-
Brownian motion). They concluded an order of mag-
nitude greater diffusion rates than predicted based on
macrorheology of CF sputum, but still more than 300-
fold slower than the diffusion of the same particles in wa-
ter. These conclusions are subject to the concerns raised
throughout the review, namely that effective diffusivity
is not well-defined for transient sub-diffusion, giving a
different diffusivity at every timescale. Indeed, identical
500 nm particles have been studied in reconstituted hu-
man bronchial epithelial mucus, across a range of mucus
wt% solids spanning healthy to moderate CF disease pro-
gression, and all PT data reveal transient sub-diffusive
behavior [40]. Furthermore, there is no study to date
that confirms equivalence of micro and macro rheology
of CF sputum. Nonetheless, the trends revealed in this
study are valuable, i.e., relative mobilities based on ef-
fective diffusivity at a common fixed timescale are valid
qualitative metrics of diffusive mobility.
PT has further been a powerful tool in facilitating the
development of methods to enhance nanoparticle diffu-
sion through mucus, such as developing muco-inert par-
ticles coated with hydrophilic polymers [35] or the use
of mucolytics to aid nanoparticle transport [105, 113].
Rather than measuring only ensemble-averaged diffusion
rates, such as with FRAP, the ability of PT to resolve
motions on an individual particle basis has enabled a
sensitive method to assess the performance of different
particle formulations. For example, Wang and Lai found
that high grafting density of low MW polyethylene glycol
(PEG) on polymeric nanoparticle surfaces could enable
rapid particle diffusion in mucus compared to particles
coated with PEG at lower grafting densities, achieving
effective diffusivities over 1 second timescales in mucus
only 7-fold reduced compared to in water [2].
While PT is a robust technique for quantifying trans-
port of a large number of individual particles in mucus
and other extracellular barriers, there are a number of
limitations to note. First, the tracked object must be suf-
ficiently bright and retain adequate signal-to-noise ratio
during microscopy (i.e. limited photobleaching). Thus,
it is difficult if not impossible to employ PT to measure
the transport of proteins and very small biological sys-
tems. Second, current microscopy methods are typically
limited to 2D rather than 3D video microscopy.
Due to the limited thickness of the focal plane, small
nanoparticles that inherently have greater diffusivity
quickly diffuse out of the focal plane, limiting the dura-
tion over which particles can be tracked to no more than
a few seconds. This naturally raises concerns whether
diffusion measurements made on the order of only a few
seconds can accurately predict the transport of parti-
cles over physiologically relevant time scales of several to
many minutes or even longer. This potential discrepancy
was highlighted recently when comparing the transport
of 100 nm nanoparticles using PT (shorter-time scale dif-
fusion) versus FRAP (longer-time scale diffusion), which
yielded significant differences in the calculated mobile
fractions (43% versus 24%, respectively) [114]. The lack
of proper statistical weighting of particle traces can also
significantly bias the calculated averages and distribu-
tions of nanoparticle diffusivities [48].
For the purposes of assessing passage times of all drug
carrier particles above ∼200 nm in mucus barriers, which
do not exhibit Brownian motion, a serious challenge
arises that is discussed in greater detail in Section 4. Suf-
fice to say, such non-Brownian, transient sub-diffusive
motion is due to the viscoelasticity of the mucus gel,
whose entropic fluctuations are not simply white noise.
Rather, the fluctuations have colored noise arising from
the timescales of memory in the elastic network; parti-
cle diffusion that feels these elastic network fluctuations
will be sub-diffusive over all timescales of memory, and
then transition to simple Brownian motion for timescales
beyond the longest memory of the mucus gel. This sit-
uation requires extreme care in modeling the underlying
stochastic process, in validating models based on exper-
imental data, in parameter estimation, and especially in














nesses, since there are virtually no theoretical analogs of
the Brownian motion formulas for mean passage times
and passage time distributions! These challenges are dis-
cussed in Section 4. However, a fundamental requirement
for transient sub-diffusive processes, which describe all
particles above 200 nm in mucus, is to capture sufficiently
long particle trajectories via PT such that one can assess
the longest timescales of memory across the fluid volume.
For this purpose, much longer observations of the parti-
cles of interest in mucus are required than the current 30
s duration particle tracks at 60 fps in most of our studies
thus far [40].
Finally, particle tracking analysis, despite the aid of
tracking software, continues to require substantial user
supervision and intervention to ensure accurate extrac-
tion of position-time series. There has been significant
progress toward the goal of fully automated tracking,
and dozens of effective methods have been developed
that are capable, given ideal conditions, automatically
converting image data into position-time series particle
paths [108, 115, 116]. However, given the conditions com-
monly encountered in experimental data—such as spa-
tiotemporal heterogeneity, variable background intensity,
photobleaching, and low signal-to-noise ratio (SNR)—
analyzing PT videos remains a labor intensive process.
This not only limits the throughput of the experiments,
but also introduces user-variations in tracking analysis
[81]. Over the last decade, machine learning tools have
rapidly advanced the field of computer imaging [117, 118].
This emerging technology has been adapted to the task
of automated particle tracking, processing 4D image data
into position-time series particle paths [81]. Using a type
of computer algorithm called a convolutional neural net-
work, the neural network tracker provides full automa-
tion with substantially improved accuracy over existing
methods, over a broad range of experimental conditions
commonly encountered in the field of drug delivery. This
technology promises to enable broad adoption of PT as a
standard laboratory tool for quantifying particle mobility
in micron scale biological systems.
6. CONCLUSION
Our aim in this review has been to frame the goals of
mucosal drug-loaded particle delivery in terms of tech-
nologies required to control physiologically relevant, one-
sided diffusive passage times: from deposition at the mu-
cus interface, through the mucosal barrier, to the epithe-
lium. If one can control particle passage times from de-
position to absorption by epithelial tissue, then one can
control drug dosage and rate of uptake via drug carrier
particle design. The design space of particles consists of
size, surface chemistry, and stability while transporting
in mucus. The states-of-the-art for the requisite exper-
imental and theoretical technologies for control of one-
sided passage times of drug carrier particles through mu-
cosal barriers have been reviewed, highlighting remaining
hurdles and prospects for overcoming them.
The passage-time perspective is an extension of the
prevalent assessment in mucosal drug delivery based on
effective diffusivity, estimated from experimental data
over a fixed timescale (cf. [3, 31, 32, 35, 44, 96, 99–107].
When particle diffusion is Brownian, e.g., small molecules
and Class 1 (Figure 1) nanoparticles in a homogeneous
mucus of a prescribed thickness, then the full theoreti-
cal power of Brownian motion (exact formulas for mean
first passage time and passage time distribution) can be
applied to gain a rigorous quantitative assessment of one-
sided passage times from free diffusion experiments on a
short, fixed timescale. Furthermore, the scaling of pas-
sage times with respect to particle size, mucus viscosity
and layer thickness, are all explicitly known. We further
discussed how to generalize these results for two physi-
ologically relevant violations of the ideal scenario: het-
erogeneity in the viscosity and thickness of the mucus
layer. The scaling behavior of the Stokes-Einstein rela-
tion already gives hints at the averaging results we pre-
sented: heterogeneity in viscosity can be replaced with
an averaged viscosity, due to the linear scaling of mean
first passage time with viscosity (and with particle size),
whereas the scaling with depth of the layer is quadratic,
yielding non-intuitive mean first passage time results due
to modulations in the air-mucus interface.
For non-Brownian motion typical of Class 2 and 3 par-
ticles in mucus depicted in Figure 1, the fixed timescale,
effective diffusivity approach is only qualitative, and only
applicable for the timescales of experimental observa-
tion, which are typically much shorter than passage times
through organ mucosal barriers. Thus, effective diffu-
sivity does not provide quantitative estimates of passage
times for 200 nm and larger drug-carrier particles for mu-
cosal drug delivery. In Section 4 we summarize a theo-
retical strategy to rigorously assess physiologically rel-
evant, one-sided passage time distributions, relying on
data from emerging 4D (3D + time) particle tracking
technologies discussed in Section 5. When simple Brow-
nian motion is violated (essentially all particles 200 nm
in size or larger in typical human mucus) due to a combi-
nation of steric interactions with, entropic fluctuations
of, electrostatic interactions with, and transient bind-
ing interactions (directly or through third party molec-
ular anchors) with, the mucus macromolecular network.
We likewise discussed viscoelastic heterogeneity of mucus
and non-uniformity in layer depth. In all such particle-
mucus scenarios, mobility is strongly time-dependent, so
that none of the fixed timescale experiments and mobility
characterizations are sufficient to extrapolate to passage
times. Intriguing open questions remain as to how to
simulate passage times for transient, sub-diffusive motion
through a heterogeneous viscoelastic medium. Solutions
to these questions and the development of the requisite
experimental and theoretical technologies are the focus
of current research among the authors and collaborators.
Finally, we cannot overemphasize the importance of














FIG. 8. Experimental techniques commonly used to quantify nanoparticle transport in mucus. (a) Diffusion chamber schematic
showing concentration-driven nanoparticle (NP) diffusion from a donor compartment into a similar acceptor compartment. NP
diffuse across a thin mucus layer sandwiched between filters of the donor and acceptor compartments. The concentration profile
of NP within the mucus layer can be used to calculate the diffusion coefficient. (b) Fluorescence recovery after photobleaching
(FRAP) schematic showing photobleaching (white circle) of a mucus specimen (dosed with red fluorescent NP) at time zero
followed by fluorescence recovery of the circular region by rapid diffusion of unbleached NP in the specimen. The time required
to reach 50% fluorescence recovery (τ12) in the photobleached region can be used to calculate the effective diffusion coefficient of
NP. Mobile and immobile fractions of NP are determined based on the ratio of the plateau intensity at the end of the recovery
profile. (c) Multiple particle tracking (MFPT) schematic showing various representative NP trajectories in mucus.
and theoretical technologies that will, hopefully within
a few years, give the capability to predict passage times
for given particles in a given mucus sample. However,
the predictions are strongly dependent on the individu-
ality of the mucus source, with very different outcomes
depending on the organ, the individual’s health versus
disease, age, and many factors that have yet to be re-
solved. We note, for example, the dramatic changes in
the diffusive mobility and estimates of passage times for
identical micron beads in human bronchial epithelial mu-
cus over a range of weight percent solids of [40], a pro-
posed biomarker in disease progression for cystic fibrosis
and COPD. Identification of lung mucus profiles for sub-
populations that stand to benefit from drug therapies
has certainly been pursued, e.g., for asthma, diabetes,
gene therapy, and COPD, and the technologies reviewed
here stand to benefit the drug particle design strategies.
Such studies reveal the importance of the mucus source
in the design of drug carrier particles, and how diffusion
in mucus of identical particles in any human organ can
vary dramatically with age, health factors, disease and
disease progression.
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